Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes-Reply

Affiliations

¹ State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

Comment

Feng Wang et al. JAMA Oncol. 2020.

. 2020 Apr 1;6(4):590.

doi: 10.1001/jamaoncol.2020.0068.

¹ State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

No abstract available

Comment on

Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.
Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH. Wang F, et al. JAMA Oncol. 2019 Oct 1;5(10):1504-1506. doi: 10.1001/jamaoncol.2019.2963. JAMA Oncol. 2019. PMID: 31415061 Free PMC article.
Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes.
Rousseau B, Vidal J, Diaz LA Jr. Rousseau B, et al. JAMA Oncol. 2020 Apr 1;6(4):589-590. doi: 10.1001/jamaoncol.2020.0065. JAMA Oncol. 2020. PMID: 32134429 No abstract available.
Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes.
Golmard L, Golmard JL, Stoppa-Lyonnet D. Golmard L, et al. JAMA Oncol. 2020 Apr 1;6(4):588-589. doi: 10.1001/jamaoncol.2020.0056. JAMA Oncol. 2020. PMID: 32134431 No abstract available.